Abstract
‘Timing’ of treatment in breast cancer may refer to intervals within a single management or between different managements. Rates of shrinkage of breast cancers in response to treatment are related to histological grade and may be used as surrogates for growth rates. Histological grade should predict appropriate timing of treatment. Four cases of locally advanced breast cancer that illustrate a number of different types of interval are presented. Two tumours of differing histological grade (II and III) had been managed by historical ‘split-course’ radiotherapy and two similar grade III tumours were managed by primary medical treatment, followed at different intervals by radiotherapy. In the grade III tumours different radiotherapy fractionation régimes and effects of varying intervals between mangements are compared. The theoretical advantage of shrinkage (leading to reoxygenation) during the gap in ‘split-course’ radiotherapy is realized only in relatively slowly growing and shrinking tumours. Grade III tumours grow rapidly. They have the potential to shrink rapidly in response to appropriate treatment, namely intensive chemotherapy or radiotherapy but not hormones. Inadequate treatment leads to growth in intervals between individual doses, whether of drugs or radiation, and to failure of local control. The advantage of surgery or primary medical treatment will be lost if the interval between managements is too long in relation to the volume doubling time. Histological grade is a good guide of this parameter; the grade III tumours are particularly vulnerable to gaps in treatment.
Similar content being viewed by others
References
Rosen PP, Fracchia AA, Urban JA, Schottenfeld D, Robbins GF: 'Residual' mammary carcinoma following simulated partial mastectomy. Cancer 35: 739–747, 1975
Morgan DAL, Galea MH, Berridge J, Blamey RW, Elston CW, Ellis IO: Post-mastectomy radiotherapy in patients at high risk of locoregional recurrence: a randomized trial. The Breast 1: 151, 1992
Dische S, Joslin CAF, Miller S, Bell NL, Holmes JC: The breast radiation injury litigation and the clinical oncologist. Clinical Oncology 10: 367–371, 1998
Hewitt HB, Wilson CW: The effect of tissue oxygen tension on the radio-sensitivity of leukaemia cells irradiated in situ in the livers of leukaemic mice. Br J Cancer 13: 675–684, 1959
Fowler JF, Morgan RL, Wood CAP: Pre-therapeutic experiments with the fast neutron beam from the Medical Research Council cyclotron. 1. The biological and physical advantages and problems of neutron therapy. Br J Radiol 36: 77–80, 1963
Sambrook, DK: Clinical trial of a modified ('split-course') technique of X-ray therapy in malignant tumours. Clin Radiol 13: 1–18, 1962
Withers HR, Taylor JMG, Maciejewski B: The hazard of accelerated tumour clonogen repopulation during radiotherapy. Act Oncol 27: 131–146, 1988
Fowler JF, Lindstrom MJ: Loss of local control with prolongation in radiotherapy. Int J Radiation Oncology Biol Phys 23: 457–467, 1992
Saunders MI, Dische S: Continuous, hyperfractionated, acelerated radiotherapy (CHART). Sem Radiation Oncol 2: 41–44, 1992
Johnson AE, Bennett MH, Cheung CWD, Cox SJ, Sales JELS: The management of individual breast cancers. The Breast 4: 100–111, 1995
Cheung CWD, Johnson AE: Carcinoma of the breast: measurement and the management of treatment. II. The regression of tumours. Br J Radiol 64: 121–132, 1991
Johnson AE, Shekhdar J: Interval cancers in the NHS breast screening programme. Br J Radiol 68: 862–869, 1995
Orton, CG and Ellis F: A simplification in the use of the NSD concept in practical radiotherapy. Br J Radiol 46: 529–537, 1973
Fowler JF: How worthwhile are short schedules in radiotherapy? A series of exploratory calculations. Radiother Oncol 18: 165–181, 1990
Fowler JF: The phantom of tumour treatment - continually rapid proliferation unmasked. Radiother Oncol 22: 156–158, 1991
Fowler JF: Modelling altered fractionation schedules. Br J Radiol Suppl 24: 187–192, 1992
Cheung CWD, Johnson AE: Carcinoma of the breast: measurement and the management of treatment. I. The value of the data. Br J Radiol 64: 29–36, 1991
Ashton-Key M, Campbell ID, Rew DA, Taylor I, Stradling R, Coddington R, Wilson GD: The histochemical evaluation of proliferation in breast carcinomas labelled in vivo with bromodeoxyuridine. The Breast 2: 42–47, 1993
Steel GG: Growth kinetics of tumours. Clarendon Press, Oxford 1977, pp 40–52
Johnson AE: Problems associated with randomized controlled clinical trials in breast cancer. J Eval Clin Pract 4: 119–126, 1998
Johnson AE: Riposte to guest commentaries on ‘Problems associated with randomized controlled clinical trials in breast cancer’. J Eval Clin Pract 4: 231–236, 1998
Bennett MH: In vivo labelling of human tumours with bromodeoxyuridine: a histopathologist's view. Br J Radiol Suppl 24: 168–173, 1992
Wilson GD, Dische S, Saunders MI: Studies with bromodeoxyuridine in head and neck cancer and accelerated radiotherapy. Radiother Oncol 36: 189–197, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johnson, A. The timing of treatment in breast cancer: gaps and delays in treatment can be harmful. Breast Cancer Res Treat 60, 201–209 (2000). https://doi.org/10.1023/A:1006441018271
Issue Date:
DOI: https://doi.org/10.1023/A:1006441018271